肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
10期
686-688
,共3页
王伟%郭庚%刘跃亭%蒯东%陈来照
王偉%郭庚%劉躍亭%蒯東%陳來照
왕위%곽경%류약정%괴동%진래조
垂体腺瘤%黏蛋白1%侵袭性
垂體腺瘤%黏蛋白1%侵襲性
수체선류%점단백1%침습성
Pituitary adenoma%Mucin1%Invasion
目的 探讨垂体腺瘤中黏蛋白1(MUC1)的表达与肿瘤侵袭性的关系.方法 采用免疫组织化学法检测26例侵袭性垂体腺瘤和29例非侵袭性垂体腺瘤患者肿瘤组织中MUC1的表达.结果 侵袭性垂体腺瘤组织中MUC1高表达,阳性率为76.92%(20/26);非侵袭性垂体腺瘤组织中MUC1为弱阳性表达或不表达,阳性率为27.57%(8/29),两者差异有统计学意义(x2=13.35,P< 0.01).功能性垂体腺瘤组织中MUC1阳性率为44.82%(13/35),非功能垂体腺瘤中MUC1阳性表达率为75.00%(15/20),两者差异无统计学意义(x2=6.13,P> 0.01).结论 MUC1在侵袭性垂体腺瘤组织中的表达及分布特点可作为垂体腺瘤侵袭性的辅助鉴别诊断指标,有可能作为垂体腺瘤免疫治疗的靶抗原.
目的 探討垂體腺瘤中黏蛋白1(MUC1)的錶達與腫瘤侵襲性的關繫.方法 採用免疫組織化學法檢測26例侵襲性垂體腺瘤和29例非侵襲性垂體腺瘤患者腫瘤組織中MUC1的錶達.結果 侵襲性垂體腺瘤組織中MUC1高錶達,暘性率為76.92%(20/26);非侵襲性垂體腺瘤組織中MUC1為弱暘性錶達或不錶達,暘性率為27.57%(8/29),兩者差異有統計學意義(x2=13.35,P< 0.01).功能性垂體腺瘤組織中MUC1暘性率為44.82%(13/35),非功能垂體腺瘤中MUC1暘性錶達率為75.00%(15/20),兩者差異無統計學意義(x2=6.13,P> 0.01).結論 MUC1在侵襲性垂體腺瘤組織中的錶達及分佈特點可作為垂體腺瘤侵襲性的輔助鑒彆診斷指標,有可能作為垂體腺瘤免疫治療的靶抗原.
목적 탐토수체선류중점단백1(MUC1)적표체여종류침습성적관계.방법 채용면역조직화학법검측26례침습성수체선류화29례비침습성수체선류환자종류조직중MUC1적표체.결과 침습성수체선류조직중MUC1고표체,양성솔위76.92%(20/26);비침습성수체선류조직중MUC1위약양성표체혹불표체,양성솔위27.57%(8/29),량자차이유통계학의의(x2=13.35,P< 0.01).공능성수체선류조직중MUC1양성솔위44.82%(13/35),비공능수체선류중MUC1양성표체솔위75.00%(15/20),량자차이무통계학의의(x2=6.13,P> 0.01).결론 MUC1재침습성수체선류조직중적표체급분포특점가작위수체선류침습성적보조감별진단지표,유가능작위수체선류면역치료적파항원.
Objective To investigate the relationship between expression of mucin1 (MUC1) and tumor invasion in pituitary adenomas.Methods The expression of MUC1 was detected by immunohistochemical analysis in 26 tissues of invasive pituitary adenoma and 29 of non-invasive pituitary adenoma.Results The expression of MUC1 in invasive pituitary adenomas tissues was 76.92 % (20/26).It was weakly positive or negative in non-invasive pituitary adenoma tissues,and the positive rate was 27.57 % (8/29).There was significant difference in two groups (x2 =13.35,P < 0.01).The expression of MUC1 in functional pituitary adenomas was 44.82 % (13/35) and was 75.00 % (15/20) in non-functional pituitary adenomas.There were no significant difference in two groups (x2 =6.13,P > 0.01).Conclusions Over-expression and aberrant localization of MUC1 in invasive pituitary adenoma may act as distinguishing diagnostic markers of invasive pituitary adenoma.MUC1 might be as the target of immunotherapy of invasive pituitary adenoma.